SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
SEC Accession No. 0001072613-23-000105
Filing Date
2023-02-13
Accepted
2023-02-13 16:08:56
Documents
1
Group Members
ARCH VENTURE FUND X OVERAGE, L.P.ARCH VENTURE PARTNERS X OVERAGE, L.P.ARCH VENTURE PARTNERS X, L.P.ARCH VENTURE PARTNERS X, LLCKEITH CRANDELLKRISTINA BUROWROBERT NELSENSTEVEN GILLIS

Document Format Files

Seq Description Document Type Size
1 ARCH VENTURE FUND X, L.P. - VERVE THERAPEUTICS, INC. -- SCH 13G/A(#1E) arch-sch13g_18696.htm SC 13G/A 81509
  Complete submission text file 0001072613-23-000105.txt   83325
Mailing Address 8755 W. HIGGINS ROAD, SUITE 1025 CHICAGO IL 60631
Business Address 8755 W. HIGGINS ROAD, SUITE 1025 CHICAGO IL 60631 773-380-6600
ARCH Venture Fund X, L.P. (Filed by) CIK: 0001757011 (see all company filings)

IRS No.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SC 13G/A

Mailing Address 201 BROOKLINE AVENUE SUITE 601 BOSTON MA 02215
Business Address 201 BROOKLINE AVENUE SUITE 601 BOSTON MA 02215 (978) 501-3026
Verve Therapeutics, Inc. (Subject) CIK: 0001840574 (see all company filings)

IRS No.: 824800132 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SC 13G/A | Act: 34 | File No.: 005-92605 | Film No.: 23618448
SIC: 2834 Pharmaceutical Preparations